Key Highlights :
The North America antibody testing market is expected to grow from US$ 3,308.90 million in 2021 to US$ 5,185.67 million by 2028, with a CAGR of 6.6% from 2021 to 2028. The market is driven by increasing demand for antibody tests due to the growing prevalence of chronic diseases and rising awareness about the importance of early diagnosis and treatment.
The North America antibody testing market is segmented by type, application, and end-user. By type, the market is further divided into immunoassays, lateral flow assays, ELISA, and western blot. By application, the market is further divided into infectious diseases, autoimmune diseases, and others. By end-user, the market is further divided into hospitals, research institutes, and others.
The key players in the North America antibody testing market are Abbott, Abcam plc, Agilent Technologies, Inc., BD, BIO-RAD Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Trinity Biotech, and Zeus Scientific. These players are focusing on product launches and collaborations to expand their product portfolio and strengthen their market position.
This report provides an in-depth analysis of the North America antibody testing market, including market drivers, trends, opportunities, and challenges. It also provides a comprehensive overview of the competitive landscape of the industry, including key players, their market share, product offerings, and strategies.
Key Market Segments:
By Type
• Immunoassays
• Lateral Flow Assays
• ELISA
• Western Blot
By Application
• Infectious Diseases
• Autoimmune Diseases
• Others
By End-User
• Hospitals
• Research Institutes
• Others
By Region
• The USA
• Europe
• Japan
• China
• India
• Southeast Asia
• South America
• South Africa
• Rest of World
Key Players
• Abbott
• Abcam plc
• Agilent Technologies, Inc.
• BIO-RAD Laboratories Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Trinity Biotech
• Zeus Scientific